Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > For Notable quick question.

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 02, 2021 10:47am

144 Views

Post# 34077086

RE:For Notable quick question.

I find all these deals at once reassuring & discouraging. Why can't a 20 yr old company, who may have an edge on these newer companies, ink a deal? Are we an unwanted dance partner, or is Coffey pricing us in the stratosphere? Pela is the real deal...sell it!!!!!

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles